P174  Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Conclusion PsARC responses greater than placebo were seen as early as W2, with stable response rates from W12 in both SELECT-PsA-1 and SELECT-PsA-2. Statistically significantly higher response rates versus ADA were observed by W20. Differences in W24 PsARC responses versus placebo and versus ADA were genera lly consistent across baseline characteristics and UPA-15mg mono/combination therapy. P174 Table 1:Modified PsARC response rates at W2 to W24 in SELECT-PsA-1 and SELECT-PsA-2 trialsStudy and week of assessmentTreatment armResponse rate % (95% CI)Response rate difference % (95% CI) UPA-placeboRespo nse rate difference % (95% CI) UPA-ADASELECT-PsA-1W2Placebo (n = 423)27.2 (22.9-31.4)14.8 (8.5-21.1)** −2.3 (−9.0-4.3)ADA (n = 429)44.3 (39.6-49.0)UPA-15mg (n = 429)42.0 (37.3-46.6)W12Placebo (n = 423)54.6 (49.9-59.4)23.7 (17.6-29.9)**2.8 ( −2.8-8.4)ADA (n = 429)75.5 (71.5-79.6)UPA-15mg (n = 429)78.3 (74.4-82.2)W16Placebo (n = 423)55.1 (50.3-59.8)24.4 (18.3-30.5)**1.9 ( −3.6-7.4)ADA (n = 429)77.6 (73.7-81.6)UPA-15mg (n = 429)79.5 (75.7-83.3)W20Placebo (n = 423)62.4 (57.8-67.0)21.3 (15.5-27.1)**6.3 (1.0-11.6)*ADA (n = 429)77.4 (73.4-81.3)UPA-15mg (n = 429)83.7 (80.2-87.2)W24Placebo (n = 423)59.3 (54.7-64.0)24.3 (18.5-30.2)**7.0 (1.7-12.3)*ADA (n = 429)76.7 (72.7-80.7)UPA-15mg (n = 429)83.7 (80.2-87.2)SELECT-PsA-2W2Placebo (n = 212)25.5 (19.6-31.3)22.4 (13.5-31.3)**-UPA-15mg (n = 211)47.9 (41.1-54.6)W12Placebo (n = 212)36.3 (29.8-42.8)34.3 (25.4-43.2)**-UPA-15mg (n = 21...
Source: Rheumatology - Category: Rheumatology Source Type: research